Posted on March 8th, 2009 by
A recent study conducted by the pharmaceutical company Amgen reveals that the drug denosumab significantly increased bone mineral density among women with early- and late-stage postmenopausal osteoporosis.
Osteoporosis is a disease that affects the bones, making them fragile, weak, and prone to fractures. Fractures related to osteoporosis typically occur in the hip, spine, and wrist. Osteoporosis is a major public health issue, affecting an estimated 44 million Americans and approximately 55% of people over the age of 50. Women are particularly vulnerable to osteoporosis as they may lose up to 20% of their bone mass in the five to seven years following menopause.
In this current study, 332 patients were treated with either twice-yearly injections of denosumab or a placebo. The following was observed:
Amgen expects that the results of its larger study, which evaluated denosumab’s impact on the reduction of fracture risk among postmenopausal women with osteoporosis, will be available later this year.
Reference: Amgen. Pivotal Phase 3 data show denosumab increased bone density at multiple skeletal sites in early and later stage postmenopausal women. Available at: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1125003.
Related News: Denosumab Improves Bone Density in Breast Cancer Patients (12/18/2007)
Copyright © 2010 CancerConsultants. All Rights Reserved.
You must be logged-in to the site to post a comment.